Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Stroke

  Free Subscription


Articles published in Am Heart J

Retrieve available abstracts of 113 articles:
HTML format



Single Articles


    May 2022
  1. OKAZAKI O, Higashino Y, Yokoya K, An Y, et al
    Prognosis of elderly non-valvular atrial fibrillation patients stratified by B-type natriuretic peptide: ELDERCARE-AF subanalysis.
    Am Heart J. 2022 May 11. pii: S0002-8703(22)00094.
    PubMed     Abstract available


  2. HUIJBOOM HFM, Maarse M, Aarnink E, van Dijk VF, et al
    COMPARE LAAO: Rationale and design of the randomized controlled trial 'COMPARing Effectiveness and safety of Left Atrial Appendage Occlusion to standard of care for atrial fibrillation patients at high stroke risk and ineligible to use oral anticoagul
    Am Heart J. 2022 May 7. pii: S0002-8703(22)00085.
    PubMed     Abstract available


  3. CANTOR WJ, Tan M, Berwanger O, Lavi S, et al
    Morphine and Clinical Outcomes in Patients with ST segment elevation Myocardial Infarction Treated with Fibrinolytic and Antiplatelet Therapy: Insights from the TREAT Trial.
    Am Heart J. 2022 May 6. pii: S0002-8703(22)00089.
    PubMed     Abstract available


  4. WAZNI O, Boersma L, Healey JS, Mansour M, et al
    Comparison of Anticoagulation with Left Atrial Appendage Closure after AF Ablation: Rationale and Design of the OPTION randomized trial.
    Am Heart J. 2022 May 5. pii: S0002-8703(22)00088.
    PubMed     Abstract available


  5. GAO W, Zhong X, Ma Y, Huang D, et al
    A Randomized Multicenter Trial to Evaluate Early Invasive Strategy for Patients with Acute ST-segment Elevation Myocardial Infarction Presenting 24-48 Hours from Symptom Onset: protocol of the RESCUE-MI study.
    Am Heart J. 2022 May 4. pii: S0002-8703(22)00087.
    PubMed     Abstract available


    April 2022
  6. SINGER DE, Atlas SJ, Go AS, Lopes RD, et al
    ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals (GUARD-AF): Rationale and Design of the GUARD-AF Randomized Trial of Screening for Atrial Fibrillation with a 14-day Patch-Based Continuous ECG Monitor.
    Am Heart J. 2022 Apr 23. pii: S0002-8703(22)00080.
    PubMed     Abstract available


    March 2022
  7. DUCROCQ G, Bhatt DL, Lee JJ, Kui N, et al
    Balance of Benefit and Risk of Ticagrelor in Patients With Diabetes and Stable Coronary Artery Disease According to Bleeding Risk Assessment With the CRUSADE Score: Data From THEMIS and THEMIS PCI: Abbreviated title: Bleeding risk stratification of ti
    Am Heart J. 2022 Mar 20. pii: S0002-8703(22)00055.
    PubMed     Abstract available


  8. TIAN X, Zuo Y, Chen S, Meng X, et al
    Distinct triglyceride-glucose trajectories are associated with different risks of incident cardiovascular disease in normal-weight adults.
    Am Heart J. 2022 Mar 3. pii: S0002-8703(22)00047.
    PubMed     Abstract available


    February 2022
  9. JONES AE, McCarty MM, Brito JP, Noseworthy PA, et al
    Randomized Evaluation of Decision Support Interventions for Atrial Fibrillation: Rationale and Design of the RED-AF study.
    Am Heart J. 2022 Feb 23. pii: S0002-8703(22)00042.
    PubMed     Abstract available


  10. O'NEILL WW, Anderson M, Burkhoff D, Grines CL, et al
    Improved Outcomes in Patients with Severely Depressed LVEF Undergoing Percutaneous Coronary Intervention with Contemporary Practices: Impella-Supported High-Risk Percutaneous Coronary Intervention in Patients with Severely Depressed LVEF.
    Am Heart J. 2022 Feb 19. pii: S0002-8703(22)00039.
    PubMed     Abstract available


  11. LINDER M, Higgen FL, Voigtlander L, Weimann J, et al
    Stroke events after transcatheter aortic valve implantation: Temporal relationships and affected brain regions.
    Am Heart J. 2022 Feb 8. pii: S0002-8703(22)00030.
    PubMed     Abstract available


  12. CHO MS, Kang DY, Oh YS, Lee CH, et al
    Edoxaban-Based Long-Term Antithrombotic Therapy in Patients with Atrial Fibrillation and Stable Coronary Disease: Rationale and Design of the Randomized EPIC-CAD Trial.
    Am Heart J. 2022 Feb 8. pii: S0002-8703(22)00023.
    PubMed     Abstract available


    January 2022
  13. BAYKANER T, Pundi K, Lin B, Lu Y, et al
    The ENHANCE-AF Clinical Trial to Evaluate an Atrial Fibrillation Shared Decision-Making Pathway: Rationale and Study Design.
    Am Heart J. 2022 Jan 26. pii: S0002-8703(22)00013.
    PubMed     Abstract available


  14. ECKMAN MH, Wise R, Knochelmann C, Mardis R, et al
    Electronic Health Record-Embedded Decision Support to Reduce Stroke Risk in Patients with Atrial Fibrillation - Study Protocol.
    Am Heart J. 2022 Jan 23. pii: S0002-8703(22)00012.
    PubMed     Abstract available


  15. GENCER B, Eisen A, Berger D, Nordio F, et al
    Edoxaban vs. Warfarin in High-risk Patients with Atrial Fibrillation: A Comprehensive Analysis of High-Risk Subgroups.
    Am Heart J. 2022 Jan 3. pii: S0002-8703(21)00499.
    PubMed     Abstract available


  16. FARJAT AE, Virdone S, Thomas LE, Kakkar AK, et al
    The importance of the design of observational studies in comparative effectiveness research: Lessons from the GARFIELD-AF and ORBIT-AF registries.
    Am Heart J. 2022;243:110-121.
    PubMed     Abstract available


  17. BUTALA NM, Song Y, Shen C, Cohen DJ, et al
    Effect of intensive versus limited monitoring on clinical trial conduct and outcomes: A randomized trial.
    Am Heart J. 2022;243:77-86.
    PubMed     Abstract available


    December 2021
  18. SIDHU MS, Lyubarova R, Bangalore S, Bonaca MP, et al
    Challenges of Long-term Dual Antiplatelet Therapy Use Following Acute Coronary Syndromes: Patient Selection for Long-term DAPT After ACS.
    Am Heart J. 2021 Dec 18. pii: S0002-8703(21)00478.
    PubMed     Abstract available


  19. ULLAL AJ, Holmes DN, Lytle BL, Matsouaka RA, et al
    Achievement and Quality Measure Attainment in Patients Hospitalized with Atrial Fibrillation: Results from the Get With The Guidelines(R) - Atrial Fibrillation (GWTG-AFIB) Registry.
    Am Heart J. 2021 Dec 18. pii: S0002-8703(21)00475.
    PubMed     Abstract available


    November 2021
  20. ANTONIO GUTIERREZ J, Ruff CT, Aday AW, Gu L, et al
    Electronic Alerts to Initiate Anticoagulation Dialogue in Patients with Atrial Fibrillation.
    Am Heart J. 2021 Nov 19. pii: S0002-8703(21)00452.
    PubMed     Abstract available


    September 2021
  21. SALAH HM, Khan Minhas AM, Khan MS, Khan SU, et al
    Trends in Hospitalizations for Heart Failure, Acute Myocardial Infarction, and Stroke in the United States from 2004-2018.
    Am Heart J. 2021 Sep 25. pii: S0002-8703(21)00238.
    PubMed     Abstract available


  22. KORSHOLM K, Damgaard D, Valentin JB, Packer EJS, et al
    Left Atrial Appendage Occlusion versus Novel Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation: Rationale and Design of the Multicenter Randomized Occlusion-AF Trial.
    Am Heart J. 2021 Sep 16. pii: S0002-8703(21)00226.
    PubMed     Abstract available


  23. NARCISSE DI, Ford CB, Weissler EH, Lippmann SJ, et al
    The association of healthcare disparities and patient-specific factors on clinical outcomes in peripheral artery disease.
    Am Heart J. 2021;239:135-146.
    PubMed     Abstract available


  24. KIM K, Yang PS, Jang E, Yu HT, et al
    Increased risk of ischemic stroke and systemic embolism in hyperthyroidism-related atrial fibrillation: A nationwide cohort study.
    Am Heart J. 2021 Sep 1. pii: S0002-8703(21)00224.
    PubMed     Abstract available


    August 2021
  25. BONNESEN MP, Diederichsen SZ, Isaksen JL, Frederiksen KS, et al
    Atrial Fibrillation Burden and Cognitive Decline in Elderly Patients Undergoing Continuous Monitoring.
    Am Heart J. 2021 Aug 21. pii: S0002-8703(21)00204.
    PubMed     Abstract available


    July 2021
  26. CHRISTENSEN DM, Butt JH, Fosbol E, Kober L, et al
    Admission Rates During a Second COVID-19 Lockdown.
    Am Heart J. 2021 Jul 15. pii: S0002-8703(21)00180.
    PubMed     Abstract available


    June 2021
  27. ABE M, Ozaki Y, Takahashi H, Ishii M, et al
    Relation of renal function to mid-term prognosis of stable angina patients with high- or low-dose pitavastatin treatment: REAL-CAD substudy.
    Am Heart J. 2021 Jun 23. pii: S0002-8703(21)00165.
    PubMed     Abstract available


  28. OVERWYK K, Yin X, Tong X, Coleman King SM, et al
    Response to letters-to-the-editor for publication: "Defect-free care trends in the Paul Coverdell National Acute Stroke Program (PCNASP), 2008-2018. American Heart Journal. 2021;232:177-184. doi:10.1016/j.ahj.2020.11.010."
    Am Heart J. 2021;236:112.
    PubMed    


  29. THOMAS S
    Re: Defect-free care trends in the Paul Coverdell National Acute Stroke Program, program, 2008-2018.
    Am Heart J. 2021;236:110-111.
    PubMed    


    May 2021
  30. SIDEBOTTOM AC, Miedema MD, Benson G, Vacquier M, et al
    The Impact of a Population-based Prevention Program on Cardiovascular Events: Findings from the Heart of New Ulm Project.
    Am Heart J. 2021 May 3. pii: S0002-8703(21)00112.
    PubMed     Abstract available


  31. MADSEN JMM, Jacobsen MRR, Sabbah M, Topal DGG, et al
    Long-Term Prognostic Outcomes and Implication of Oral Anticoagulants in Patients with New-Onset Atrial Fibrillation following ST-Segment Elevation Myocardial Infarction.
    Am Heart J. 2021 May 3. pii: S0002-8703(21)00114.
    PubMed     Abstract available


  32. SHI X, He J, Lin M, Liu C, et al
    Comparative effectiveness of team-based care with a clinical decision support system versus team-based care alone on cardiovascular risk reduction among patients with diabetes: Rationale and design of the D4C trial.
    Am Heart J. 2021 May 3. pii: S0002-8703(21)00111.
    PubMed     Abstract available


    March 2021
  33. KIVINIEMI T, Bustamante-Munguira J, Olsson C, Jeppsson A, et al
    A randomized prospective multicenter trial for stroke prevention by prophylactic surgical closure of the left atrial appendage in patients undergoing bioprosthetic aortic valve surgery - LAA-CLOSURE trial protocol.
    Am Heart J. 2021 Mar 30. pii: S0002-8703(21)00087.
    PubMed     Abstract available


  34. TURAKHIA M, Sundaram V, Smith SN, Ding V, et al
    Efficacy of a Centralized, Blended Electronic and Human Intervention to Improve Direct Oral Anticoagulant Adherence: Smartphones to improve rivaroxaban ADHEREnce in Atrial Fibrillation (SmartADHERE) A Randomized Clinical Trial: SmartADHERE rivaroxaban
    Am Heart J. 2021 Mar 4. pii: S0002-8703(21)00065.
    PubMed     Abstract available


    February 2021
  35. AKAO M, Yasuda S, Kaikita K, Ako J, et al
    Rivaroxaban Monotherapy versus Combination Therapy According to Patient Risk of Stroke and Bleeding in Atrial Fibrillation and Stable Coronary Disease: AFIRE trial sub-analysis.
    Am Heart J. 2021 Feb 28. pii: S0002-8703(21)00063.
    PubMed     Abstract available


  36. GE Z, Gao XF, Kan J, Kong XQ, et al
    Comparison of 1-month Versus 12-month Dual Antiplatelet Therapy after Implantation of Drug-eluting Stents Guided by either Intravascular Ultrasound or Angiography in Patients with Acute Coronary Syndrome: Rationale and Design of Prospective, Multicent
    Am Heart J. 2021 Feb 20. pii: S0002-8703(21)00053.
    PubMed     Abstract available


  37. CAPELL WH, Barnathan ES, Piazza G, Spyropoulos AC, et al
    Rationale and Design for the Study of Rivaroxaban to Reduce Thrombotic Events, Hospitalization and Death in Outpatients with COVID-19: the PREVENT-HD Study.
    Am Heart J. 2021 Feb 9. pii: S0002-8703(21)00033.
    PubMed     Abstract available


  38. BLUMER V, Rivera M, Corbalan R, Becker RC, et al
    Rivaroxaban versus Warfarin in Patients with Atrial Fibrillation Enrolled in Latin America: Insights from ROCKET AF.
    Am Heart J. 2021 Feb 8. pii: S0002-8703(21)00036.
    PubMed     Abstract available


  39. HUSAINI M, Esmaeeli A, Thangam M, Doering M, et al
    Synthesis of systematic reviews of percutaneous device closure of patent foramen ovale (PFO) for prevention of recurrent cryptogenic stroke: Redundant publications and methodological deficiencies.
    Am Heart J. 2021;232:57-60.
    PubMed     Abstract available


    January 2021
  40. SEN S, Redd K, Trivedi T, Moss K, et al
    Periodontal Disease, Atrial Fibrillation and Stroke.
    Am Heart J. 2021 Jan 24. pii: S0002-8703(21)00013.
    PubMed     Abstract available


  41. DE GROOT JR, Ruff CT, Murphy SA, Hamershock RA, et al
    Edoxaban versus Warfarin in Patients with Atrial Fibrillation in Relation to the Risk of Stroke: A Secondary Analysis of the ENGAGE AF-TIMI 48 Study.
    Am Heart J. 2021 Jan 22. pii: S0002-8703(21)00017.
    PubMed     Abstract available


  42. THIELE H, Freund A, Gimenez MR, de Waha-Thiele S, et al
    Extracorporeal life support in patients with acute myocardial infarction complicated by cardiogenic shock - Design and rationale of the ECLS-SHOCK trial.
    Am Heart J. 2021 Jan 8. pii: S0002-8703(21)00004.
    PubMed     Abstract available


  43. BAO X, Borne Y, Xu B, Orho-Melander M, et al
    Growth differentiation factor-15 is a biomarker for all-cause mortality but less evident for cardiovascular outcomes: a prospective study: Abbreviated title: GDF-15, all-cause mortality and CVD.
    Am Heart J. 2021 Jan 6. pii: S0002-8703(21)00002.
    PubMed     Abstract available


  44. SMILOWITZ NR, Subashchandran V, Yuriditsky E, Horowitz JM, et al
    Thrombosis in hospitalized patients with viral respiratory infections versus COVID-19.
    Am Heart J. 2021;231:93-95.
    PubMed     Abstract available


  45. VALGIMIGLI M, Cao D, Makkar RR, Bangalore S, et al
    Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
    Am Heart J. 2021;231:147-156.
    PubMed     Abstract available


    December 2020
  46. ROME BN, Gagne JJ, Avorn J, Kesselheim AS, et al
    Non-Warfarin Oral Anticoagulant Copayments and Adherence in Atrial Fibrillation:A Population-Based Cohort Study.
    Am Heart J. 2020 Dec 21. pii: S0002-8703(20)30412.
    PubMed     Abstract available


  47. CARNICELLI AP, Hong H, Giugliano RP, Connolly SJ, et al
    Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale: From the COMBINE AF (A COllaboration between Multiple instit
    Am Heart J. 2020 Dec 6. pii: S0002-8703(20)30401.
    PubMed     Abstract available


  48. KHAN H, Hanif M, Khan MA, Mirza E, et al
    Letter to the editor: Discontinuation rates of warfarin versus direct acting oral anticoagulants in clinical practice.
    Am Heart J. 2020;230:101.
    PubMed    


    November 2020
  49. OVERWYK KJ, Yin X, Tong X, King SMC, et al
    Defect-free Care trends in the Paul Coverdell National Acute Stroke Program, 2008-2018.
    Am Heart J. 2020 Nov 27. pii: S0002-8703(20)30392.
    PubMed     Abstract available


  50. KAWASHIMA H, Soliman O, Wang R, Ono M, et al
    Rationale and design of a randomized clinical trial comparing safety and efficacy of Myval transcatheter heart valve versus contemporary transcatheter heart valves in patients with severe symptomatic aortic valve stenosis: the LANDMARK trial.
    Am Heart J. 2020 Nov 5. pii: S0002-8703(20)30368.
    PubMed     Abstract available


    October 2020
  51. NORDENSKJOLD AM, Agewall S, Atar D, Baron T, et al
    Randomized evaluation of beta blocker and ACE-inhibitor/angiotensin receptor blocker treatment in patients with myocardial infarction with non-obstructive coronary arteries (MINOCA-BAT): Rationale and design.
    Am Heart J. 2020;231:96-104.
    PubMed     Abstract available


  52. SALAH HM, Al'Aref SJ, Khan MS, Al-Hawwas M, et al
    Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials.
    Am Heart J. 2020;232:10-22.
    PubMed     Abstract available


  53. NATHAN AS, Yang L, Geng Z, Dayoub EJ, et al
    Oral anticoagulant use in patients with atrial fibrillation and mitral valve repair.
    Am Heart J. 2020;232:1-9.
    PubMed     Abstract available


  54. NICHOLLS SJ, Lincoff AM, Bays HE, Cho L, et al
    Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of Bempedoic acid on cardiovascular events in patients with statin intolerance.
    Am Heart J. 2020 Oct 23. pii: S0002-8703(20)30346.
    PubMed     Abstract available


  55. SHAVADIA JS, Wilson J, Edmonston D, Platt A, et al
    Statins and atherosclerotic cardiovascular outcomes in patients on incident dialysis and with atherosclerotic heart disease.
    Am Heart J. 2020 Oct 20. pii: S0002-8703(20)30341.
    PubMed     Abstract available


  56. GIBSON CM, Kastelein JJP, Phillips AT, Aylward PE, et al
    Rationale and design of ApoA-I event reducing in ischemic syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myoc
    Am Heart J. 2020 Oct 13. pii: S0002-8703(20)30335.
    PubMed     Abstract available


  57. GUIMARAES HP, de Barros E Silva PGM, Liporace IL, Sampaio RO, et al
    A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial.
    Am Heart J. 2020 Oct 9. pii: S0002-8703(20)30277.
    PubMed     Abstract available


  58. WIGGERS H, Kober L, Gislason G, Schou M, et al
    The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 x 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with
    Am Heart J. 2020 Oct 8. pii: S0002-8703(20)30276.
    PubMed     Abstract available


    September 2020
  59. GRUBB AF, Pumill CA, Greene SJ, Wu A, et al
    Tobacco smoking in patients with heart failure and coronary artery disease: A 20-year experience at Duke University medical center.
    Am Heart J. 2020 Sep 24. pii: S0002-8703(20)30264.
    PubMed     Abstract available


  60. SHAIKH A, Ochani RK, Khan MS, Riaz H, et al
    Contribution of individual components to composite endpoints in contemporary cardiovascular randomized controlled trials.
    Am Heart J. 2020 Sep 14. pii: S0002-8703(20)30254.
    PubMed     Abstract available


    August 2020
  61. KAWAKAMI H, Nolan MT, Phillips K, Scuffham PA, et al
    Cost-effectiveness of combined catheter ablation and left atrial appendage closure for symptomatic atrial fibrillation in patients with high stroke and bleeding risk.
    Am Heart J. 2020 Aug 18. pii: S0002-8703(20)30238.
    PubMed     Abstract available


  62. KWON S, Lee SR, Choi EK, Choe WS, et al
    Non-vitamin K antagonist oral anticoagulants in very elderly east Asians with atrial fibrillation: A nationwide population-based study.
    Am Heart J. 2020;229:81-91.
    PubMed     Abstract available


  63. ELHARRAM M, Sharma A, White W, Bakris G, et al
    Timing of randomization after an acute coronary syndrome in patients with type 2 diabetes mellitus.
    Am Heart J. 2020;229:40-51.
    PubMed     Abstract available


  64. MIRWAIS M, Reynolds M
    Extending physicians' reach in grasping AF symptoms.
    Am Heart J. 2020;226:250-251.
    PubMed    


    July 2020
  65. AL-KHATIB SM, Pokorney SD, Al-Khalidi HR, Haynes K, et al
    Underuse of oral anticoagulants in privately insured patients with atrial fibrillation: A population being targeted by the IMplementation of a randomized controlled trial to imProve treatment with oral AntiCoagulanTs in patients with Atrial Fibrillati
    Am Heart J. 2020;229:110-117.
    PubMed     Abstract available


  66. LI Y, Jing Q, Wang B, Wang X, et al
    Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of t
    Am Heart J. 2020;228:1-7.
    PubMed     Abstract available


    May 2020
  67. ARMSTRONG PW, Bogaerts K, Welsh R, Sinnaeve PR, et al
    The Second Strategic Reperfusion Early After Myocardial Infarction (STREAM-2) study optimizing pharmacoinvasive reperfusion strategy in older ST-elevation myocardial infarction patients.
    Am Heart J. 2020;226:140-146.
    PubMed     Abstract available


    April 2020
  68. JACKSON LR 2ND, Kim S, Blanco R, Thomas L, et al
    Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: Results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
    Am Heart J. 2020;226:85-93.
    PubMed     Abstract available


  69. WHITE HD, Stewart RAH, Dalby AJ, Stebbins A, et al
    In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c <7% are associated with lower major cardiovascular events.
    Am Heart J. 2020;225:97-107.
    PubMed     Abstract available


  70. YANG Y, Zhou Z, Pan Y, Chen H, et al
    Randomized trial of argatroban plus recombinant tissue-type plasminogen activator for acute ischemic stroke (ARAIS): Rationale and design.
    Am Heart J. 2020;225:38-43.
    PubMed     Abstract available


  71. EHRLICH ME, Kolls BJ, Roettig M, Monk L, et al
    Implementation of Best Practices-Developing and Optimizing Regional Systems of Stroke Care: Design and Methodology.
    Am Heart J. 2020;222:105-111.
    PubMed     Abstract available


    March 2020
  72. KARTHIKEYAN G, Connolly SJ, Ntsekhe M, Benz A, et al
    The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation.
    Am Heart J. 2020;225:69-77.
    PubMed     Abstract available


  73. THIBERT MJ, Hawkins NM, Andrade JG
    Clinical decision support for atrial fibrillation in primary care: Steps forward.
    Am Heart J. 2020;224:54-56.
    PubMed    


  74. HUANG L, Tian M, Yu J, Li Q, et al
    Interim effects of salt substitution on urinary electrolytes and blood pressure in the China Salt Substitute and Stroke Study (SSaSS).
    Am Heart J. 2020;221:136-145.
    PubMed     Abstract available


  75. GESKE JB, Driver CN, Yogeswaran V, Ommen SR, et al
    Comparison of expected and observed outcomes for septal myectomy in hypertrophic obstructive cardiomyopathy.
    Am Heart J. 2020;221:159-164.
    PubMed     Abstract available


    February 2020
  76. AKAO M, Yamashita T, Suzuki S, Okumura K, et al
    Impact of creatinine clearance on clinical outcomes in elderly atrial fibrillation patients receiving apixaban: J-ELD AF Registry subanalysis.
    Am Heart J. 2020;223:23-33.
    PubMed     Abstract available


    January 2020
  77. WEIR MR, Ashton V, Moore KT, Shrivastava S, et al
    Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease.
    Am Heart J. 2020;223:3-11.
    PubMed     Abstract available


  78. PASSMAN R
    Atrial fibrillation detection using implantable cardiac monitors: Are we being too revealing?
    Am Heart J. 2020;219:137-139.
    PubMed    


  79. REIFFEL JA, Verma A, Kowey PR, Halperin JL, et al
    Rhythm monitoring strategies in patients at high risk for atrial fibrillation and stroke: A comparative analysis from the REVEAL AF study.
    Am Heart J. 2020;219:128-136.
    PubMed     Abstract available


  80. CASSESE S, Ndrepepa G, Byrne RA, Laugwitz KL, et al
    Ticagrelor-based antiplatelet regimens in patients with atherosclerotic artery disease-A meta-analysis of randomized clinical trials.
    Am Heart J. 2020;219:109-116.
    PubMed     Abstract available


  81. SAMSKY M, Krucoff M, Althouse AD, Abraham WT, et al
    Clinical and regulatory landscape for cardiogenic shock: A report from the Cardiac Safety Research Consortium ThinkTank on cardiogenic shock.
    Am Heart J. 2020;219:1-8.
    PubMed    


    December 2019
  82. SALAHUDDIN T, Kittelson J, Tardif JC, Shah PK, et al
    Association of high-density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome: A case-cohort analysis of the dal-Outcomes trial.
    Am Heart J. 2019;221:60-66.
    PubMed     Abstract available


  83. MAZUREK M, Teutsch C, Diener HC, Dubner SJ, et al
    Safety and effectiveness of dabigatran at 2 years: Final outcomes from Phase II of the GLORIA-AF registry program.
    Am Heart J. 2019;218:123-127.
    PubMed     Abstract available


    November 2019
  84. DE FERRARI GM, Stevens SR, Ambrosio G, Leonardi S, et al
    Low-density lipoprotein cholesterol treatment and outcomes in patients with type 2 diabetes and established cardiovascular disease: Insights from TECOS.
    Am Heart J. 2019;220:82-88.
    PubMed     Abstract available


  85. MAGGIONI AP, Dondi L, Andreotti F, Pedrini A, et al
    Four-year trends in oral anticoagulant use and declining rates of ischemic stroke among 194,030 atrial fibrillation patients drawn from a sample of 12 million people.
    Am Heart J. 2019;220:12-19.
    PubMed     Abstract available


  86. EVANS CR, Long DL, Howard G, McClure LA, et al
    C-reactive protein and stroke risk in blacks and whites: The REasons for Geographic And Racial Differences in Stroke cohort.
    Am Heart J. 2019;217:94-100.
    PubMed     Abstract available


    October 2019
  87. GARCIA DA, Fisher DA, Mulder H, Wruck L, et al
    Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
    Am Heart J. 2019;221:1-8.
    PubMed     Abstract available


  88. WELSH RC, Peterson ED, De Caterina R, Bode C, et al
    Applying contemporary antithrombotic therapy in the secondary prevention of chronic atherosclerotic cardiovascular disease.
    Am Heart J. 2019;218:100-109.
    PubMed     Abstract available


  89. POKORNEY SD, Holmes DN, Shrader P, Thomas L, et al
    Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation.
    Am Heart J. 2019;220:145-154.
    PubMed     Abstract available


  90. SHAVADIA JS, Zheng Y, Green JB, Armstrong PW, et al
    Associations between beta-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease.
    Am Heart J. 2019;218:92-99.
    PubMed     Abstract available


  91. NIDORF SM, Fiolet ATL, Eikelboom JW, Schut A, et al
    The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics.
    Am Heart J. 2019;218:46-56.
    PubMed     Abstract available


  92. PAGIDIPATI NJ, Zheng Y, Green JB, McGuire DK, et al
    Association of obesity with cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: Insights from TECOS.
    Am Heart J. 2019;219:47-57.
    PubMed     Abstract available


  93. JONES WS, Kennedy KF, Hawkins BM, Attaran RR, et al
    Expanding opportunities to understand quality and outcomes of peripheral vascular interventions: The ACC NCDR PVI Registry.
    Am Heart J. 2019;216:74-81.
    PubMed     Abstract available


    September 2019
  94. BRENNAN JM, Wruck L, Pencina MJ, Clare RM, et al
    Claims-based cardiovascular outcome identification for clinical research: Results from 7 large randomized cardiovascular clinical trials.
    Am Heart J. 2019;218:110-122.
    PubMed     Abstract available


    August 2019
  95. PARK S, Ahn JM, Lee K, Kwon O, et al
    Long-term (10-year) outcomes of stenting or bypass surgery for acute coronary syndromes and stable ischemic heart disease with unprotected left main coronary artery disease.
    Am Heart J. 2019;218:9-19.
    PubMed     Abstract available


  96. RAY KK, Nicholls SJ, Ginsberg HD, Johansson JO, et al
    Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial.
    Am Heart J. 2019;217:72-83.
    PubMed     Abstract available


    June 2019
  97. CANNON CP, Khan I, Klimchak AC, Sanchez RJ, et al
    Simulation of impact on cardiovascular events due to lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease.
    Am Heart J. 2019;216:30-41.
    PubMed     Abstract available


  98. OSTERGAARD L, Andersson NW, Kristensen SL, Dahl A, et al
    Risk of stroke subsequent to infective endocarditis: A nationwide study.
    Am Heart J. 2019;212:144-151.
    PubMed     Abstract available


    May 2019
  99. MENTIAS A, Shantha G, Adeola O, Barnes GD, et al
    Role of diabetes and insulin use in the risk of stroke and acute myocardial infarction in patients with atrial fibrillation: A Medicare analysis.
    Am Heart J. 2019;214:158-166.
    PubMed     Abstract available


  100. GAZIANO TA, Pandya A, Sy S, Jardim TV, et al
    Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States.
    Am Heart J. 2019;214:77-87.
    PubMed     Abstract available


    April 2019
  101. INOHARA T, Shrader P, Pieper K, Blanco RG, et al
    Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II.
    Am Heart J. 2019;213:81-90.
    PubMed     Abstract available


  102. AKERBLOM A, Wojdyla DM, Wallentin L, James SK, et al
    Ticagrelor in patients with heart failure after acute coronary syndromes-Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.
    Am Heart J. 2019;213:57-65.
    PubMed     Abstract available


  103. GUTIERREZ JA, Bhatt DL, Banerjee S, Glorioso TJ, et al
    Risk of obstructive coronary artery disease and major adverse cardiac events in patients with noncoronary atherosclerosis: Insights from the Veterans Affairs Clinical Assessment, Reporting, and Tracking (CART) Program.
    Am Heart J. 2019;213:47-56.
    PubMed     Abstract available


  104. HAAS S, Camm AJ, Bassand JP, Angchaisuksiri P, et al
    Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF.
    Am Heart J. 2019;213:35-46.
    PubMed     Abstract available


    February 2019
  105. PETERSON ED, Ashton V, Chen YW, Wu B, et al
    Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation.
    Am Heart J. 2019;212:113-119.
    PubMed     Abstract available


    January 2019
  106. BLAKE SR, Shahzad A, Aggarwal SK, Kumar A, et al
    Radial versus femoral vascular access in ST-elevation myocardial infarction: Are the results of femoral operators unfairly represented in observational research?
    Am Heart J. 2019;210:81-87.
    PubMed     Abstract available


  107. KOSMIDOU I, Redfors B, Chen S, Crowley A, et al
    C-reactive protein and prognosis after percutaneous coronary intervention and bypass graft surgery for left main coronary artery disease: Analysis from the EXCEL trial.
    Am Heart J. 2019;210:49-57.
    PubMed     Abstract available


  108. MACHLINE-CARRION MJ, Santucci EV, Damiani LP, Bahit C, et al
    An international cluster-randomized quality improvement trial to increase the adherence to evidence-based therapies for acute ischemic stroke and transient ischemic attack patients: Rationale and design of the BRIDGE STROKE Trial.
    Am Heart J. 2019;207:49-57.
    PubMed     Abstract available


  109. GONG E, Gu W, Sun C, Turner EL, et al
    System-integrated technology-enabled model of care to improve the health of stroke patients in rural China: protocol for SINEMA-a cluster-randomized controlled trial.
    Am Heart J. 2019;207:27-39.
    PubMed     Abstract available


    November 2018
  110. ALEXANDER KP, Brouwer MA, Mulder H, Vinereanu D, et al
    Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial.
    Am Heart J. 2018 Nov 22. pii: S0002-8703(18)30296.
    PubMed     Abstract available


  111. HELD C, White HD, Stewart RAH, Davies R, et al
    Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial.
    Am Heart J. 2018;208:65-73.
    PubMed     Abstract available


    October 2018
  112. POKORNEY SD, Gersh BJ, Ahmad A, Al-Khatib SM, et al
    Stroke prevention in atrial fibrillation: Closing the gap.
    Am Heart J. 2018;210:29-38.
    PubMed    


  113. DAVISON WJ, Myint PK, Clark AB, Potter JF, et al
    Blood pressure differences between home monitoring and daytime ambulatory values and their reproducibility in treated hypertensive stroke and TIA patients.
    Am Heart J. 2018;207:58-65.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Stroke is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: